Loading company…
Omivera provides CellEKT, a platform for assessing kinase selectivity and target engagement in living cells.
Omivera B.V. offers CellEKT, a contract research service that uses molecular probes and proteomics to assess kinase selectivity and target engagement. It serves pharmaceutical and biotechnology companies working on drug discovery. Based in Leiden, Netherlands, the company raised EUR 350,000 in seed funding from InnovationQuarter in February 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in